BMS 181184

Drug Profile

BMS 181184

Alternative Names: BMY 28762; BMY 28801; BMY 28864

Latest Information Update: 16 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class AIDS vaccines; Antifungals; Antivirals; Fungal vaccines
  • Mechanism of Action Cell membrane modulators; HIV envelope protein gp120 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued HIV infections; Mycoses; Pneumocystis pneumonia

Most Recent Events

  • 27 Feb 2001 No-Development-Reported for Pneumocystis pneumonia in USA (Parenteral)
  • 27 Feb 2001 No-Development-Reported for HIV infections treatment in United Kingdom (Parenteral)
  • 27 Feb 2001 No-Development-Reported for HIV infections treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top